Published in Clin Cancer Res on November 15, 2013
Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther (2015) 0.99
Aurora kinase A in gastrointestinal cancers: time to target. Mol Cancer (2015) 0.90
Aurora-A promotes chemoresistance in hepatocelluar carcinoma by targeting NF-kappaB/microRNA-21/PTEN signaling pathway. Oncotarget (2014) 0.88
Advances in targeted therapies and new promising targets in esophageal cancer. Oncotarget (2015) 0.87
AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers. Mol Oncol (2014) 0.85
p53, a potential predictor of Helicobacter pylori infection-associated gastric carcinogenesis? Oncotarget (2016) 0.79
Correlation of decreased expression of PHLDA1 protein with malignant phenotype of gastric adenocarcinoma. Int J Clin Exp Pathol (2015) 0.77
Activation of EIF4E by Aurora kinase A depicts a novel druggable axis in everolimus resistant cancer cells. Clin Cancer Res (2017) 0.76
Functional Significance of Aurora Kinases-p53 Protein Family Interactions in Cancer. Front Oncol (2016) 0.75
Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases. J Exp Clin Cancer Res (2016) 0.75
Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis. Oncogenesis (2017) 0.75
AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827. Oncol Rep (2015) 0.75
Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib. Mol Oncol (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet (1998) 8.91
The cellular geography of aurora kinases. Nat Rev Mol Cell Biol (2003) 6.40
A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A (2001) 6.25
Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J (1991) 4.33
Gastric cancer. Lancet (2003) 3.96
AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell (2003) 3.50
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol (2009) 3.47
The MDM2-p53 interaction. Mol Cancer Res (2003) 3.43
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet (2003) 3.38
The impact of underreported Veterans Affairs data on national cancer statistics: analysis using population-based SEER registries. J Natl Cancer Inst (2009) 3.09
The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol (2010) 3.08
Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem (2004) 2.11
Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene (2006) 2.09
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood (2010) 2.08
Aurora kinase inhibitors--rising stars in cancer therapeutics? Mol Cancer Ther (2010) 1.91
MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets (2005) 1.83
Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer (2001) 1.77
Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol (2011) 1.72
K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroenterol Hepatol (2000) 1.64
DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res (2000) 1.51
Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst (1999) 1.44
The aurora kinase A regulates GSK-3beta in gastric cancer cells. Oncogene (2008) 1.41
Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res (2008) 1.37
The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther (2012) 1.33
Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer (2008) 1.32
Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett (2011) 1.22
Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res (2005) 1.19
Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). Am J Gastroenterol (2010) 1.17
Loss of TFF1 is associated with activation of NF-κB-mediated inflammation and gastric neoplasia in mice and humans. J Clin Invest (2011) 1.15
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer (2008) 1.10
Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology (2013) 1.07
Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci (2006) 1.04
Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol (2007) 1.01
Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells. FEBS Lett (2011) 0.97
p73 and p63 protein stability: the way to regulate function? Biochem Pharmacol (2003) 0.95
Aurora kinase A in Barrett's carcinogenesis. Hum Pathol (2010) 0.88
Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library. J Biol Chem (2009) 0.86
Regulation of CXCR4-mediated invasion by DARPP-32 in gastric cancer cells. Mol Cancer Res (2012) 0.83
The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Eur J Med Res (2011) 0.83
MDM2 splice variants predominantly localize to the nucleoplasm mediated by a COOH-terminal nuclear localization signal. Mol Cancer Res (2007) 0.83
Chemotherapy in gastric cancer: a never ending saga. Ann Oncol (2003) 0.82
Integrating bioinformatics and clinicopathological research of gastrointestinal stromal tumors: identification of aurora kinase A as a poor risk marker. Ann Surg Oncol (2012) 0.82
Copy-number increase of AURKA in gastric cancers in a Chinese population: a correlation with tumor progression. Med Oncol (2010) 0.81
Establishment and characterization of a cisplatin-resistant cell line (IGSK-1) from a poorly differentiated gastric adenocarcinoma. Hum Cell (2007) 0.77
p53 has a direct apoptogenic role at the mitochondria. Mol Cell (2003) 8.98
Formin-2, polyploidy, hypofertility and positioning of the meiotic spindle in mouse oocytes. Nat Cell Biol (2002) 3.34
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood (2010) 2.08
Aurora kinase inhibitors--rising stars in cancer therapeutics? Mol Cancer Ther (2010) 1.91
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2012) 1.63
Epigenetic silencing of somatostatin in gastric cancer. Dig Dis Sci (2010) 1.61
Imaging protein interactions with bioluminescence resonance energy transfer (BRET) in plant and mammalian cells and tissues. Proc Natl Acad Sci U S A (2007) 1.48
Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells. Gastroenterology (2010) 1.45
Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res (2008) 1.37
deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol (2003) 1.33
The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther (2012) 1.33
Interaction of Helicobacter pylori with gastric epithelial cells is mediated by the p53 protein family. Gastroenterology (2008) 1.33
Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer (2008) 1.32
Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat (2008) 1.32
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol (2011) 1.30
p53 Family: Role of Protein Isoforms in Human Cancer. J Nucleic Acids (2011) 1.26
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med (2011) 1.22
Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res (2008) 1.20
Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res (2005) 1.19
Promoter DNA hypermethylation in gastric biopsies from subjects at high and low risk for gastric cancer. Int J Cancer (2010) 1.18
t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Res (2008) 1.15
Loss of TFF1 is associated with activation of NF-κB-mediated inflammation and gastric neoplasia in mice and humans. J Clin Invest (2011) 1.15
Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. Am J Pathol (2005) 1.11
Pathogenic bacterium Helicobacter pylori alters the expression profile of p53 protein isoforms and p53 response to cellular stresses. Proc Natl Acad Sci U S A (2012) 1.11
Glutathione peroxidase 7 protects against oxidative DNA damage in oesophageal cells. Gut (2011) 1.08
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther (2010) 1.07
Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia. Gastroenterology (2013) 1.07
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer (2012) 1.06
Overexpression of the 32-kilodalton dopamine and cyclic adenosine 3',5'-monophosphate-regulated phosphoprotein in common adenocarcinomas. Cancer (2003) 1.06
Deciphering the unique microRNA signature in human esophageal adenocarcinoma. PLoS One (2013) 1.05
Silencing of glutathione peroxidase 3 through DNA hypermethylation is associated with lymph node metastasis in gastric carcinomas. PLoS One (2012) 1.02
Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells. Clin Cancer Res (2008) 1.02
Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia (2007) 1.01
Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. Am J Pathol (2009) 1.00
BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. J Clin Invest (2011) 1.00
Distal regions of the human IFNG locus direct cell type-specific expression. J Immunol (2010) 0.99
Coamplified and overexpressed genes at ERBB2 locus in gastric cancer. Int J Cancer (2004) 0.98
ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res (2012) 0.98
Molecular dissection of 17q12 amplicon in upper gastrointestinal adenocarcinomas. Mol Cancer Res (2006) 0.97
p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Res (2004) 0.96
p73 protein regulates DNA damage repair. FASEB J (2011) 0.96
Lmo2 induces hematopoietic stem cell-like features in T-cell progenitor cells prior to leukemia. Stem Cells (2013) 0.96
Cofactor of BRCA1: a novel transcription factor regulator in upper gastrointestinal adenocarcinomas. Cancer Res (2006) 0.95
Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma. Cancer (2013) 0.95
Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas. Neoplasia (2006) 0.95
Dopamine and cAMP regulated phosphoprotein MW 32 kDa is overexpressed in early stages of gastric tumorigenesis. Surgery (2010) 0.94
Targeting aurora kinases in cancer treatment. Curr Drug Targets (2011) 0.93
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 0.92
Methylation-dependent activation of CDX1 through NF-κB: a link from inflammation to intestinal metaplasia in the human stomach. Am J Pathol (2012) 0.91
Location-specific epigenetic regulation of the metallothionein 3 gene in esophageal adenocarcinomas. PLoS One (2011) 0.91
DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib. Gastroenterology (2011) 0.91
Clustering of molecular alterations in gastroesophageal carcinomas. Neoplasia (2004) 0.91
t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer. Mol Cancer (2010) 0.90
Proinflammatory cytokines and bile acids upregulate ΔNp73 protein, an inhibitor of p53 and p73 tumor suppressors. PLoS One (2013) 0.90
Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237). Drug Metab Lett (2014) 0.90